Kava and St. John's wort: Current evidence for use in mood and anxiety disorders

Journal of Alternative and Complementary Medicine

Volumn 15, Issue 8, 2009, Pages 827-836

  Sarris, Jerome ^a   Kavanagh, David J ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMITRIPTYLINE; CAFFEINE; CHLORZOXAZONE; CITALOPRAM; DEBRISOQUINE; FLAVONOID; FLUOXETINE; HYPERFORIN; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; KAVA; KAVALACTONE DERIVATIVE; KAWAIN; MAPROTILINE; MIDAZOLAM; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CLINICAL TRIAL; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSTHYMIA; GASTROINTESTINAL SYMPTOM; GENERALIZED ANXIETY DISORDER; HERB DRUG INTERACTION; HERBAL MEDICINE; HUMAN; HYPERICUM PERFORATUM; HYPOMANIA; LIVER TOXICITY; LOW DRUG DOSE; MAJOR DEPRESSION; MANIA; MOOD DISORDER; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PANIC; PIPER METHYSTICUM; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOSIS; RISK BENEFIT ANALYSIS; SEASONAL AFFECTIVE DISORDER; SEROTONIN SYNDROME; SIDE EFFECT; SKIN TOXICITY; SOCIAL PHOBIA; UNSPECIFIED SIDE EFFECT;

ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY; BICYCLO COMPOUNDS; HUMANS; HYPERICUM; KAVA; MOOD DISORDERS; PERYLENE; PHLOROGLUCINOL; PHYTOTHERAPY; PLANT EXTRACTS; TERPENES;

EID: 70350123076     PISSN: 10755535     EISSN: None     Source Type: Journal    
DOI: 10.1089/acm.2009.0066     Document Type: Article

References (118)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th "Text Revision" ed. Arlington: American Psychiatric Association, 2000.
2. Kessler RC, Merikangas KR, Wang PS. Prevalence, comorbidity, and service utilization for mood disorders in the United States at the beginning of the twenty-first century. Annu Rev Clin Psychol 2007;3:137-158.
3. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617-627. (Pubitemid 40973437)
4. Alonso J, Angermeyer MC, Bernert S, et al. Prevalence of mental disorders in Europe: Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004;420:21-27.
5. Belmaker RH, Agam G. Major depressive disorder. NEJM 2008;358:55-68.
6. Hindmarch I. Expanding the horizons of depression: Beyond the monoamine hypothesis. Hum Psychopharmacol 2001;16:203-218.
7. Clark L, Sahakian B. Cognitive neuroscience and brain imaging in bipolar disorder. Dialogues Clin Neurosci 2008;10:153-163.
8. Dean B. The neurobiology of bipolar disorder: Findings using human postmortem central nervous system tissue. Aust N Z J Psychiatry 2004;38:135-140.
9. Millan M. The neurobiology and control of anxious states. Prog Neuropsychobiol 2003;70:83-244.
10. Kessler RC, Soukup J, Davis RB, et al. The use of complementary and alternative therapies to treat anxiety and depression in the United States. Am J Psychiatry 2001;158: 289-294.
11. Wu P, Fuller C, Liu X, et al. Use of complementary and alternative medicine among women with depression: Results of a national survey. Psychiatr Serv 2007;58:349-356.
12. Singh YN. Kava: An overview. J Ethnopharmacol 1992;37: 13-45.
13. Pittler MH, Ernst E. Kava extract for treating anxiety. Cochrane Database Syst Rev 2006;1:CD003383.
14. Witte S, Loew D, Gaus W. Meta-analysis of the efficacy of the acetonic kava-kava extract WS1490 in patients with non-psychotic anxiety disorders. Phytother Res 2005;19: 183-188.
15. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55.
16. Jadad A, Moore A, Carroll D, et al. Assessing the quality of reports of randomised clinical trials: Is blinding necessary? Controlled Clin Trials 1996;17:1-12. (Pubitemid 26120810)
17. Boerner RJ, Sommer H, Berger W, et al. Kava-kava extract LI 150 is as effective as opipramol and buspirone in generalised anxiety disorder: An 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients. Phytomedicine 2003;10 (suppl 4):38-49.
18. Munte TF, Heinze HJ, Matzke M, Steitz J. Effects of oxazepam and an extract of kava roots (Piper methysticum) on event-related potentials in a word recognition task. Neuropsychobiology 1993;27:46-53.
19. Chouinard G. Issues in the clinical use of benzodiazepines: Potency, withdrawal, and rebound. J Clin Psychiatry 2004;65(suppl 5):7-12.
20. Volz HP, Kieser M. Kava-kava extract WS 1490 versus placebo in anxiety disorders: A randomized placebocontrolled 25-week outpatient trial. Pharmacopsychiatry 1997;30:1-5.
21. Blumenthal M, Hall T, Goldberg A, et al., eds. The ABC Clinical Guide to Herbs. Austin: American Botanical Council, 2003.
22. Jussofie A, Schmiz A, Hiemke C. Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain. Psychopharmacology (Berl) 1994;116:469-474.
23. Davies LP, Drew CA, Duffield P, et al. Kava pyrones and resin: Studies on GABAA, GABAB and benzodiazepine binding sites in rodent brain. Pharmacol Toxicol 1992;71: 120-126.
24. Boonen G, Haberlein H. Influence of genuine kavapyrone enantiomers on the GABA-A binding site. Planta Med 1998;64:504-506.
25. Yuan CS, Dey L, Wang A, et al. Kavalactones and dihydrokavain modulate GABAergic activity in a rat gastricbrainstem preparation. Planta Med 2002;68:1092-1096.
26. Magura EI, Kopanitsa MV, Gleitz J, et al. Kava extract ingredients, (+)-methysticin and (+/-)-kavain inhibit voltage- operated Na(+)-channels in rat CA1 hippocampal neurons. Neuroscience 1997;81:345-351.
27. Singh YN, Singh NN. Therapeutic potential of kava in the treatment of anxiety disorders. CNS Drugs 2002;16:731-743.
28. Uebelhack R, Franke L, Schewe HJ. Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum Forster (kava-kava). Pharmacopsychiatry 1998; 31:187-192.
29. Seitz U, Schule A, Gleitz J. [3H]-monoamine uptake inhibition properties of kava pyrones. Planta Med 1997;63:548-549.
30. Martin HB, McCallum M, Stofer WD, Eichinger MR. Kavain attenuates vascular contractility through inhibition of calcium channels. Planta Med 2002;68:784-789.
31. Gleitz J, Beile A, Peters T. (+/-)-Kavain inhibits veratridineactivatedvoltage- dependentNa(+)-channels insynaptosomes prepared from rat cerebral cortex. Neuropharmacology 1995;34:1133-1138.
32. Tyrer P, Baldwin D. Generalised anxiety disorder. Lancet 2006;368:2156-2166.
33. Baum SS, Hill R, Rommelspacher H. Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats. Prog Neuropsychopharmacol Biol Psychiatry 1998;22:1105-1120.
34. Mathews JM, Etheridge AS, Valentine JL, et al. Pharmacokinetics and disposition of the kavalactone kawain: Interaction with kava extract and kavalactones in vivo and in vitro. Drug Metab Dispos 2005;33:1555-1563.
35. Mathews JM, Etheridge AS, Black SR. Inhibition of human cytochrome P450 activities by kava extract and kavalactones. Drug Metab Dispos 2002;30:1153-1157.
36. Unger M, Holzgrabe U, Jacobsen W, et al. Inhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (Kava-Kava). Planta Med 2002;68:1055-1058.
37. Ma Y, Sachdeva K, Liu J, et al. Desmethoxyyangonin and dihydromethysticin are two major pharmacological kavalactones with marked activity on the induction of CYP3A23. Drug Metab Dispos 2004;32:1317-1324.
38. Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 2005;77:415-426.
39. Singh YN. Potential for interaction of kava and St. John's wort with drugs. J Ethnopharmacol 2005;100(1-2):108-113.
40. Foo H, Lemon J. Acute effects of kava, alone or in combination with alcohol, on subjective measures of impairment and intoxication and on cognitive performance. Drug Alcohol Rev 1997;16:147-155. (Pubitemid 127531298)
41. Anke J, Fu S, Ramzan I. Kavalactones fail to inhibit alcohol dehydrogenase in vitro. Phytomedicine 2006;13:192-195.
42. Coulter D. Assessment of the Risk of Hepatotoxicity with Kava Products. Geneva:WHOAppointed Committee, 2007.
43. Teschke R, Schwarzenboeck A, Hennermann KH. Kava hepatotoxicity: A clinical survey and critical analysis of 26 suspected cases. Eur J Gastroenterol Hepatol 2008;20:1182-1193.
44. Anke J, Ramzan I. Pharmacokinetic and pharmacodynamic drug interactions with kava (Piper methysticum Forst. f.). J Ethnopharmacol 2004;93(2-3):153-160.
45. Clouatre DL. Kava kava: Examining new reports of toxicity. Toxicol Lett 2004;150:85-96.
46. Stevinson C, Huntley A, Ernst E. A systematic review of the safety of kava extract in the treatment of anxiety. Drug Saf 2002;25:251-261.
47. Lude S, Torok M, Dieterle S, et al. Hepatocellular toxicity of kava leaf and root extracts. Phytomedicine 2008;15(1- 2):120-131.
48. Singh YN, Devkota AK. Aqueous kava extracts do not affect liver function tests in rats. Planta Med 2003;69:496-499.
49. Sorrentino L, Capasso A, Schmidt M. Safety of ethanolic kava extract: Results of a study of chronic toxicity in rats. Phytomedicine 2006;13:542-549.
50. Teschke R, Schwarzenboeck A, Akinci A. Kava hepatotoxicity: A European view. N Z Med J 2008;121:90-98.
51. Brown AC, Onopa J, Holck P, et al. Traditional kava beverage consumption and liver function tests in a predominantly Tongan population in Hawaii. Clin Toxicol (Phila) 2007;45:549-556.
52. Clough AR, Bailie RS, Currie B. Liver function test abnormalities in users of aqueous kava extracts. J Toxicol Clin Toxicol 2003;41:821-829.
53. Wurglics M, Schubert-Zsilavecz M. Hypericum perforatum: A 'modern' herbal antidepressant: Pharmacokinetics of active ingredients. Clin Pharmacokinet 2006;45:449-468.
54. Linde K, Berner M, Kriston L. St John's wort for major depression. Cochrane Database Syst Rev 2008;4:CD000448.
55. Roder C, Schaefer M, Leucht S. Meta-analysis of effectiveness and tolerability of treatment of mild to moderate depression with St. John's wort [in German]. Fortschr Neurol Psychiatr 2004;72:330-343.
56. Werneke U, Horn O, Taylor D. How effective is St John's wort? The evidence revisited. J Clin Psychiatry 2004;65: 611-617.
57. Whiskey E, Werneke U, Taylor D. A systematic review and meta-analysis of Hypericum perforatum in depression: A comprehensive clinical review. Int J Clin Psychopharm 2001;16:239-252.
58. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
59. Guy W, Bonato Re. CGI: Clinical Global Impressions. Manual for the ECDEU Assessment Battery. 2. Rev ed. Chevy Chase, MD: National Institute of Mental Health, 1970:12-1-12-16
60. Behnke K, Jensen GS, Graubaum HJ, Gruenwald J. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression. Adv Ther 2002;19:43-52.
61. Bjerkenstedt L, Edman GV, Alken RG, Mannel M. Hypericum extract LI 160 and fluoxetine in mild to moderate depression: A randomized, placebo-controlled multi-center study in outpatients. Eur Arch Psychiatry Clin Neurosci 2005;255:40-47.
62. Fava M, Alpert J, Nierenberg AA, et al. A double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol 2005;25:441-447.
63. Schrader E. Equivalence of St John's wort extract (Ze 117) and fluoxetine: A randomized, controlled study in mildmoderate depression. Int Clin Psychopharmacol 2000;15: 61-68.
64. Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: Randomised multicentre study of treatment for eight weeks. BMJ 1999;319:1534-1538.
65. Vorbach EU, Hubner WD, Arnoldt KH. Effectiveness and tolerance of the hypericum extract LI 160 in comparison with imipramine: Randomized double-blind study with 135 outpatients. J Geriatr PsychiatryNeurol 1994;7(suppl 1):S19-S23.
66. Vorbach EU, Arnoldt KH, Hubner WD. Efficacy and tolerability of St. John's wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10. Pharmacopsychiatry 1997;30(suppl 2):81-85.
67. Woelk H. Comparison of St John's wort and imipramine for treating depression: Randomised controlled trial. BMJ 2000;321:536-539.
68. Gastpar M, Singer A, Zeller K. Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3- VI and citalopram in patients with moderate depression: A double-blind, randomised, multicentre, placebo-controlled study. Pharmacopsychiatry 2006;39:66-75.
69. Harrer G, Hubner WD, Podzuweit H. Effectiveness and tolerance of the hypericum extract LI 160 compared to maprotiline: a multicenter double-blind study. J Geriatr Psychiatry Neurol 1994;7(suppl 1):S24-S28.
70. Wheatley D. LI 160, an extract of St. John's wort, versus amitriptyline in mildly to moderately depressed outpatients: A controlled 6-week clinical trial. Pharmacopsychiatry 1997;30(suppl 2):77-80.
71. Szegedi A, Kohnen R, Dienel A, Kieser M. Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): Randomised controlled double blind non-inferiority trial versus paroxetine. BMJ 2005; 330:503.
72. Beck AT, Ward C, Mendelson M. Beck Depression Inventory (BDI). Arch Gen Psychiatry 1961;4:561-571.
73. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John's wort) in major depressive disorder: A randomized controlled trial. JAMA 2002;287: 1807-1814.
74. Brenner R, Azbel V, Madhusoodanan S, Pawlowska M. Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: A double-blind, randomized pilot study. Clin Ther 2000;22:411-419.
75. Gastpar M, Singer A, Zeller K. Efficacy and tolerability of hypericum extract STW3 in long-term treatment with a once-daily dosage in comparison with sertraline. Pharmacopsychiatry 2005;38:78-86. (Pubitemid 40388787)
76. van Gurp G, Meterissian GB, Haiek LN, et al. St John's wort or sertraline? Randomized controlled trial in primary care. Can Fam Physician 2002;48:905-912.
77. Clement K, Covertson CR, Johnson MJ, Dearing K. St. John's wort and the treatment of mild to moderate depression: A systematic review.HolistNurs Pract 2006;20:197-203.
78. Lawvere S, Mahoney MC. St. John's wort. Am Fam Physician 2005;72:2249-2254.
79. McGarry H, Pirotta M, Hegarty K, Gunn J. General practitioners and St. John's wort: A question of regulation or knowledge? Complement Ther Med 2007;15:142-148.
80. Randlov C, Mehlsen J, Thomsen CF, et al. The efficacy of St. John's wort in patients with minor depressive symptoms or dysthymia: A double-blind placebo-controlled study. Phytomedicine 2006;13:215-221.
81. Martinez B, Kasper S, Ruhrmann S, Moller HJ. Hypericum in the treatment of seasonal affective disorders. J Geriatr Psychiatry Neurol 1994;7(suppl 1):S29-S33.
82. Wheatley D. Hypericum in seasonal affective disorder (SAD). Curr Med Res Opin 1999;15:33-37.
83. Kobak KA, Taylor LV, Warner G, Futterer R. St. John's wort versus placebo in social phobia: Results from a placebocontrolled pilot study. J Clin Psychopharmacol 2005;25: 51-58. (Pubitemid 40129382)
84. Taylor LH, Kobak KA. An open-label trial of St. John's wort (Hypericum perforatum) in obsessive-compulsive disorder. J Clin Psychiatry 2000;61:575-578.
85. Goodman W. The Yale-Brown Obsessive Compulsive Scale. Arch Gen Psychiatry 1989;46:1006-1011.
86. Kobak KA, Taylor LV, Bystritsky A, et al. St John's wort versus placebo in obsessive-compulsive disorder: Results from a double-blind study. Int Clin Psychopharmacol 2005;20:299-304.
87. Butterweck V. Mechanism of action of St John's wort in depression: What is known? CNS Drugs 2003;17:539-562. (Pubitemid 36774135)
88. Muller WE, Rolli M, Schafer C, Hafner U. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry 1997;30(suppl 2): 102-107.
89. Thiede HM, Walper A. Inhibition of MAO and COMT by hypericum extracts and hypericin. J Geriatr Psychiatry Neurol 1994;7(suppl 1):S54-S56.
90. Muller D, Pfeil T, von den Driesch V. Treating depression comorbid with anxiety: Results of an open, practiceoriented study with St John's wortWS 5572 and valerian extract in high doses. Phytomedicine 2003;10(suppl 4):25-30.
91. Marsh WL, Davies JA. The involvement of sodium and calcium ions in the release of amino acid neurotransmitters from mouse cortical slices elicited by hyperforin. Life Sci 2002;71:2645-2655.
92. Singer A, Wonnemann M, Muller WE. Hyperforin, a major antidepressant constituent of St. John's wort, inhibits serotonin uptake by elevating free intracellular Na+1. J Pharmacol Exp Ther 1999;290:1363-1368.
93. Mennini T, Gobbi M. The antidepressant mechanism of Hypericum perforatum. Life Sci 2004;75:1021-1027.
94. Zanoli P. Role of hyperforin in the pharmacological activities of St. John's wort. CNS Drug Rev 2004;10:203-218.
95. Yoshitake T, Iizuka R, Yoshitake S, et al. Hypericum perforatum L (St John's wort) preferentially increases extracellular dopamine levels in the rat prefrontal cortex. Br J Pharmacol 2004;142:414-418.
96. Pariante CM, Thomas SA, Lovestone S, et al. Do antidepressants regulate how cortisol affects the brain? Psychoneuroendocrinology 2004;29:423-447.
97. Franklin M, Hafizi S, Reed A, et al. Effect of sub-chronic treatment with Jarsin (extract of St John's wort, Hypericum perforatum) at two dose levels on evening salivary melatonin and cortisol concentrations in healthy male volunteers. Pharmacopsychiatry 2006;39:13-15.
98. Schule C, Baghai T, Ferrera A, Laakmann G. Neuroendocrine effects of Hypericum extract WS 5570 in 12 healthy male volunteers. Pharmacopsychiatry 2001;34(suppl 1): S127-S133.
99. Butterweck V, Schmidt M. St. John's wort: Role of active compounds for its mechanism of action and efficacy. Wien Med Wochenschr 2007;157(13-14):356- 361.
100. Beerhues L. Hyperforin. Phytochemistry 2006;67:2201-2207.
101. Laakmann G, Schule C, Baghai T, Kieser M. St. John's wort in mild to moderate depression: The relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 1998; 31(suppl 1):54-59.
102. Schellenberg R, Sauer S, Dimpfel W. Pharmacodynamic effects of two different hypericum extracts in healthy volunteers measured by quantitative EEG. Pharmacopsychiatry 1998;31(suppl 1):44-53.
103. Schulz HU, Schurer M, Bassler D, Weiser D. Investigation of pharmacokinetic data of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin revealed from single and multiple oral dose studies with a hypericum extract containing tablet in healthy male volunteers. Arzneimittelforschung 2005;55:561-568. (Pubitemid 41546100)
104. Wysowski D. Surveillance of prescription drug-related mortality using death certificate data. Drug Saf 2007;30: 533-540.
105. Knuppel L, Linde K. Adverse effects of St. John's wort: A systematic review. J Clin Psychiatry 2004;65:1470-1479.
106. Arroll B, Macgillivray S, Ogston S, et al. Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: A meta-analysis. Ann Fam Med 2005;3:449-456.
107. Schulz V. Safety of St. John's wort extract compared to synthetic antidepressants. Phytomedicine 2006;13:199-204.
108. Rodriguez-Landa JF, Contreras CM. A review of clinical and experimental observations about antidepressant actions and side effects produced by Hypericum perforatum extracts. Phytomedicine 2003;10:688-699.
109. Nierenberg AA, Burt T, Matthews J, Weiss AP. Mania associated with St. John's wort. Biol Psychiatry 1999;46:1707-1708.
110. Raja M, Azzoni A. Hypericum-induced mood disorders: Switch from depression to mixed episodes in two patients. Int J Psych Clin Pract 2006;10:146-148.
111. Schneck C. St. John's wort and hypomania. J Clin Psychiatry 1998;59:689.
112. Papakostas GI. Dopaminergic-based pharmacotherapies for depression. Eur Neuropsychopharmacol 2006;16:391-402.
113. Karalapillai D, Bellomo R. Convulsions associated with an overdose of St John's wort. Med J Aust 2007;186:213-214.
114. Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther 2003;73:41-50.
115. Izzo AA. Drug interactions with St. John's wort (Hypericum perforatum): A review of the clinical evidence. Int J Clin Pharmacol Ther 2004;42:139-148.
116. Moore LB, Goodwin B, Jones SA, et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A 2000; 97:7500-7502.
117. Whitten D, Myers D, Hawrelak J, Wohlmuth H. The effect of St John's wort extracts on CYP3A: A systematic review of prospective clinical trials. Br J Clin Pharmacol 2006; 62:512-526.
118. Mueller SC, Majcher-Peszynska J, Uehleke B, et al. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose. Eur J Clin Pharmacol 2006;62:29-36.